Magstim has announced that its next-generation Horizon Inspire system has received FDA clearance for transcranial magnetic stimulation (TMS) to treat patients suffering from major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression.
The Horizon Inspire system, developed by Minneapolis-based Magstim, is engineered to meet the needs of physicians by offering high-power air cooling and the capability to deliver customizable, back-to-back treatments. The system is designed for ease of use, cost-effectiveness, and portability between clinic rooms.
Built upon Magstim's existing TMS technology, which already holds prior FDA clearances, the Horizon Inspire system utilizes intuitive preset clinical workflows to streamline the treatment process. Magstim states that its system delivers precise results without pulse decay, ensuring accurate dosage. The air-cooled coil reduces downtime and eliminates additional cooling expenses, while advanced data analytics tools enhance treatment efficacy.
"Physicians, nurse practitioners, and mental health care professionals tell us that patients are searching for alternatives to pharmaceutical treatments," said Ronnie Stolec-Campo, CEO of Magstim. "FDA cleared transcranial magnetic stimulation is a proven and effective treatment with minimal side effects. We designed the Inspire to enable both experienced TMS providers as well as those who are new to TMS."
Magstim emphasizes its commitment to research, noting that it engineered the first commercially available TMS research technology. The company also highlights its unique position in the industry by not charging pay-per-use fees, maintaining a dedicated service and support team, and manufacturing its own technology.
